GlassScriptPhysician profile
Mary D Chambers
NPI 1790737674
$2,685.96
in general payments reported to CMS, 2019-2025
27 companies · $608 in 2025
The $608 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $90.36 · 2021: $290 · 2022: $313 · 2023: $388 · 2024: $536 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.36 | 2019-2025 | Liletta, Lo Loestrin Fe |
| Organon LLC | $325.93 | 2022-2025 | Nexplanon |
| Astellas Pharma US INC | $305.34 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $239.69 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.06 | 2019-2025 | |
| Pfizer INC. | $132.56 | 2019-2025 | |
| Sage Therapeutics, LLC | $107.26 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $88.19 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Agile Therapeutics, INC. | $79.40 | 2021-2024 | Twirla |
| Merck Sharp & Dohme LLC | $77.16 | 2019 | |
| Dexcom, INC. | $51.23 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $37.00 | 2025 | Paragard T 380a |
| Duchesnay USA Incorporated | $34.15 | 2019 | |
| Minerva Surgical, INC | $32.98 | 2024 | |
| Sumitomo Pharma America, INC. | $29.44 | 2025 | Myfembree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $29.10 | 2019-2023 | Balcoltra |
| Therapeuticsmd, INC. | $27.68 | 2020-2021 | |
| Biogen, INC. | $26.36 | 2024 | Zurzuvae |
| Evofem Biosciences, INC. | $24.75 | 2021 | |
| Myovant Sciences INC. | $20.73 | 2022 | |
| Intuitive Surgical, INC. | $16.63 | 2023 | Da Vinci Surgical System |
| Allergan, INC. | $14.09 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.50 | 2020 | |
| Scynexis, INC. | $12.45 | 2022 | |
| Radius Health, INC. | $12.38 | 2019 | |
| Meditrina | $12.21 | 2024 | |
| Mission Pharmacal Company | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.